| Reagan-Udall Foundation

Read more about Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long

Read more about The Effect of Diabetes M Application Use Versus Conventional Bolus Calculation in Patients With Type 1 Diabetes Mellitus

Read more about Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms

Read more about ECM Therapeutics, Inc.

We will share key learnings related to the design of our Phase 2b PRIZM study in MELAS at the primary mitochondrial diseases public workshop, hosted by the Reagan-Udall Foundation for the FDA.

Coverage

Read more about Tisento Therapeutics: Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases

Read more about The COVID Dome Trial

Read more about Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort

Subscribe to

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Shanghai Qilu Pharmaceutical Research and Development Center LTD

Effectiveness of a Therapeutic Yoga Program on Fatigue and Related Variables in Patients With Chronic Fatigue Syndrome or Long Covid

Impact of COVID-19 Pandemic on Single-stage Laparoscopic Cholecystectomy and Laparoscopic Common Bile Duct Exploration Service

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long

The Effect of Diabetes M Application Use Versus Conventional Bolus Calculation in Patients With Type 1 Diabetes Mellitus

Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms

ECM Therapeutics, Inc.

Tisento Therapeutics: Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases

The COVID Dome Trial

Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort

Subscribe for updates from the Reagan-Udall Foundation for the FDA